Greenwood Kathryn, Alford Katie, O'Leary Iain, Peters Emmanuelle, Hardy Amy, Cavanagh Kate, Field Andy P, de Visser Richard, Fowler David, Davies Matthew, Papamichail Alexandra, Garety Philippa
R&D Department, Sussex Partnership NHS Foundation Trust, Sussex Education Centre, Millview Hospital Site, Nevill Avenue, Hove, BN3 7HZ, UK.
School of Psychology, University of Sussex, Pevensey Building, Falmer, Brighton, East Sussex, BN1 9RP, UK.
Trials. 2018 Nov 20;19(1):644. doi: 10.1186/s13063-018-3023-7.
At least 40% of people with psychosis have persistent distressing symptoms despite optimal medication treatment. Cognitive behaviour therapy for psychosis (CBTp) is the only NICE-recommended individual therapy for psychosis, with effects on symptoms, distress and quality of life. Yet <10% of service-users receive it and 94% of trusts struggle to provide it. Of those offered it, 22-43% refuse or do not attend. We have developed a new pre-CBTp informed choice intervention to address knowledge and attitudes that influence uptake and implementation and now want to test it in a feasibility trial.
The design is a two-arm, feasibility randomised controlled trial (RCT), with 1:1 randomisation, stratified by participant group and site. Participants are 40 psychosis patients and 40 clinicians, who are ambivalent towards uptake or implementation of CBTp. Sites are community and inpatient services in Sussex and London. The intervention is a pre-CBT digital psychoeducation intervention designed to address identified knowledge and attitudinal barriers to uptake and implementation of CBTp, incorporating behaviour change mechanisms, and supported by animated introductory, patient and clinician stories. The comparator is the NHS choices website for CBT. The primary aim is to assess clinical feasibility (recruitment, randomisation, acceptability, use, delivery, outcome measurement, retention). A secondary aim is a preliminary evaluation of efficacy. Outcomes will be assessed at baseline, post intervention, and one-month follow-up (blind to treatment arm). The primary efficacy outcome is likelihood of offering/taking up CBTp. Secondary outcomes include knowledge and attitudes towards CBTp, illness perceptions, empowerment, psychological wellbeing (patients only) and CBTp implementation (clinicians only). Use of the intervention and CBT behaviours during the follow-up period will be recorded and captured in a feedback questionnaire. Use, acceptability and experience of outcome assessment will be explored in qualitative interviews with participants (n = 6 per group). The efficacy evaluation will report descriptive data, key model parameters and 95% highest probability density intervals in a Bayesian growth model.
This is the first feasibility trial of a digital 'informed choice' decision aid for the implementation of CBTp. If the trial proves feasible and demonstrates preliminary evidence of efficacy, a large multi-site trial will be warranted.
ISRCTN registry, ISRCTN53107879 . Registered prospectively on 2 August 2017.
尽管接受了最佳药物治疗,但至少40%的精神病患者仍有持续的痛苦症状。精神病认知行为疗法(CBTp)是唯一一项由英国国家卫生与临床优化研究所(NICE)推荐的针对精神病的个体疗法,对症状、痛苦和生活质量均有影响。然而,只有不到10%的服务使用者接受该疗法,94%的信托机构难以提供该疗法。在那些被提供该疗法的人中,22%-43%会拒绝或不参加。我们开发了一种新的CBTp前知情选择干预措施,以解决影响接受和实施该疗法的知识和态度问题,现在希望在一项可行性试验中对其进行测试。
该设计为双臂可行性随机对照试验(RCT),采用1:1随机分组,按参与者组和地点分层。参与者为40名精神病患者和40名临床医生,他们对CBTp的接受或实施持矛盾态度。地点为苏塞克斯郡和伦敦的社区及住院服务机构。干预措施是一种CBT前数字心理教育干预,旨在解决已确定的影响CBTp接受和实施的知识和态度障碍,纳入行为改变机制,并由动画介绍、患者和临床医生故事提供支持。对照为NHS选择网站上关于CBT的内容。主要目的是评估临床可行性(招募、随机分组、可接受性、使用、提供、结果测量、保留率)。次要目的是对疗效进行初步评估。将在基线、干预后和1个月随访时(对治疗组不知情)评估结果。主要疗效结果是提供/接受CBTp的可能性。次要结果包括对CBTp的知识和态度、疾病认知、赋权、心理健康(仅针对患者)以及CBTp的实施情况(仅针对临床医生)。随访期间干预措施的使用情况和CBT行为将记录在一份反馈问卷中。将通过对参与者进行定性访谈(每组6人)来探讨结果评估的使用情况、可接受性和体验。疗效评估将在贝叶斯增长模型中报告描述性数据、关键模型参数和95%最高概率密度区间。
这是第一项针对实施CBTp的数字“知情选择”决策辅助工具的可行性试验。如果该试验证明可行并显示出初步疗效证据,则有必要进行一项大型多中心试验。
ISRCTN注册库,ISRCTN53107879。于2017年8月2日前瞻性注册。